Endo International plc - FORM 10-Q - EX-10.5.1 - NORAMCO 3RD AMENDMENT TO SUPPLY AGREEMENT - May 6, 2016

Attached files

file filename
EX-10.22 - FORM OF STOCK OPTION AGREEMENT - Endo International plcex1022formofstockoptionagre.htm
EX-32.1 - CEO SECTION 906 CERTIFICATION - Endo International plcex3213312016ceo906cert.htm
EX-10.5.2 - NORAMCO 4TH AMENDMENT TO SUPPLY AGREEMENT - Endo International plcex1052noramco4thamendmentto.htm
EX-10.24 - FORM OF PERFORMANCE AWARD AGREEMENT - Endo International plcex1024formofperformanceawar.htm
EX-10.35 - FORM OF INDEMNIFICATION AGREEMENT - Endo International plcex1035endointernationalplc.htm
EX-31.1 - CEO SECTION 302 CERTIFICATION - Endo International plcex3113312016ceo302cert.htm
EX-32.2 - CFO SECTION 906 CERTIFICATION - Endo International plcex3223312016cfo906cert.htm
EX-10.28.1 - NOVARTIS SANDOZ ENDO LETTER AGREEMENT - Endo International plcex10281novartissandozendo.htm
EX-31.2 - CFO SECTION 302 CERTIFICATION - Endo International plcex3123312016cfo302cert.htm
EX-10.23 - FORM OF STOCK AWARD AGREEMENT - Endo International plcex1023formofstockawardagree.htm
10-Q - 10-Q - Endo International plcendp-3312016x10q.htm
EX-10.5.3 - NORAMCO 5TH AMENDMENT TO SUPPLY AGREEMENT - Endo International plcex1053noramco5thamendmentt.htm
Exhibit 10.5.1
The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.

THIRD AMENDMENT TO SUPPLY AGREEMENT
This Third Amendment to the April 27, 2012 Supply Agreement (the “Third Amendment”) is made as of January 1, 2015 (the “Effective Date”) by and between Endo Pharmaceuticals Inc., a Delaware limited liability company with offices at 1400 Atwater Drive, Malvern, PA 19355 (“ENDO”) and Noramco, Inc. a Georgia corporation having a principal place of business at 500 Swedes Landing Road, Wilmington, DE 19801, USA (“Noramco”) hereinafter collectively and/or individually (Parties and/or Party).
WHEREAS:
(A)The Parties hereto entered into a Supply Agreement dated April 27, 2012 (the “Agreement”), and amended the Agreement on December 12, 2013 (the “First Amendment), and on April 29, 2015 (the, “Second Amendment”), and the Parties desire to amend the Agreement as set forth herein.
NOW THE PARTIES HEREBY AGREE AS FOLLOWS:
1.Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to such terms in the Agreement.
2.For ***, in excess of the agreed volume maximum and beginning ***, purchases by Endo and Affiliates are not included in the Agreement and shall be based on availability. Price shall be determined for each request.
3.Prices for the Agreement as of the above Effective Date of this Amendment are attached.
4.Save as otherwise expressly referred to in this Amendment the terms and conditions of the Agreement shall apply in all other respects and remain in full force and effect.
IN WITNESS WHEREOF,·the parties have caused their duly authorized representatives to




execute this Third Amendment in duplicate counterparts.
ENDO PHARMACEUTICALS INC.
By:
/s/Rajiv De Silva
Name:
Rajiv De Silva
Title:
President and Chief Executive Officer
Date:
8/17/2015
NORAMCO, INC.
By:
/s/John Giannone
Name:
John Giannone
Title:
Director of US Sales
Date:
7/27/2015



Attachment
***

Stock widget

Investing forum

Endo International plc Reports

Also read